Afimmune

SME

Afimmune

Description

The entity profile has not yet been completed.

This entity is yours?
Sign in to update information and position your organization seamlessly within the European bioproduction Value Chain. Benefit from the geolocated map to showcase your expertise, projects, and initiatives. Boost your visibility and make meaningful connections within the ecosystem. Sign in

Afimmune

Address

Dublin, Ireland

Contact

info@afimmune.com

Description

The entity profile has not yet been completed.

This entity is yours?
Sign in to update information and position your organization seamlessly within the European bioproduction Value Chain. Benefit from the geolocated map to showcase your expertise, projects, and initiatives. Boost your visibility and make meaningful connections within the ecosystem.

Matchmaking

Connect with Afimmune

Position on the value chain

With the ultimate aim to create a European alliance for bioproduction in Europe, organisations have joined forces with COBIOE. Discover who are our associates.

Bio-resources and biobanking
  • Cells, tissues and humanized xeno-organs
  • Biosamples
  • Viral, phage or bacterial specimen
Identification of biotherapies
  • Target identification
  • Target validation
  • Screening
Drug design
  • Drug assessment
  • Drug engineering
  • In vitro preclinical studies
Clinical validation
  • Clinical trials
  • In vivo preclinical validation
  • Pre-industrial scale production
Production
  • Upstream processes
  • Downstream processes
  • Quality control
Market access
  • CE mark / market authorisation
  • Payment / Reimbursement
  • Care pathways

Afimmune last news

08/11/2023

Afimmune to present at the American Society of Hematology (ASH) Annual Meeting after initiating recruitment in Sickle Cell Disease trial

Dublin, Ireland, 8 November 2023: Afimmune, a clinical stage biopharmaceutical company developing novel rare disease therapeutics, today announced that recruitment has commenced in the first clinical […] The post Afimmune to present at the American Society of Hematology (ASH) Annual Meeting after initiating recruitment in Sickle Cell Disease trial appeared first on Afimmune .

18/09/2023

Afimmune's Epeleuton is granted both FDA Rare Pediatric Disease and Fast Track Designations for the treatment of Sickle Cell Disease

Dublin, Ireland, 18 September 2023: Afimmune, a clinical stage biopharmaceutical company developing novel rare disease therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted […] The post Afimmune's Epeleuton is granted both FDA Rare Pediatric Disease and Fast Track Designations for the treatment of Sickle Cell Disease appeared first on Afimmune .

19/06/2023

Afimmune joins the Sickle Cell Disease Association of America's Collaboration of Advocates for Research, Education and Science (C.A.R.E.S.) Consortium

Dublin, Ireland, 19 June 2023: Afimmune, a clinical stage biopharmaceutical company developing novel rare disease therapeutics, today announced it has been invited to join the Sickle Cell Disease […] The post Afimmune joins the Sickle Cell Disease Association of America's Collaboration of Advocates for Research, Education and Science (C.A.R.E.S.) Consortium appeared first on Afimmune .